Spyre reports positive Phase 2 SPY003 data, completing proof-of-concept for IBD trioSep 8Clinical readoutSPY001SPY002
Spyre reports mixed Phase 2 results for SPY072 in rheumatoid arthritisAug 25Clinical readoutSPY002-072Spyre Therapeutics, Inc.
Spyre Therapeutics registers Phase 2 SKYLIGHT trial of SPY072 in hidradenitis suppurativaAug 14Trial updateSPY002-072Spyre Therapeutics, Inc.
Spyre reports Phase 2 IBD data for SPY001, SPY002, sets Q4 rheumatic readoutsAug 4Quarterly updateSPY001SPY002
Sign inSign in